此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

LY4050784 在晚期或转移性实体瘤参与者中的研究

2026年11月9日 更新者:Eli Lilly and Company

LY4050784(一种选择性 SMARCA2/BRM 抑制剂)在具有 SMARCA4/BRG1 改变的晚期实体瘤恶性肿瘤中的开放标签、多中心研究

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.

研究概览

研究类型

介入性

注册 (估计的)

340

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Berlin、德国、10117
        • Charite-Universitatsmedizin Berlin
      • Essen、德国、45147
        • Universitaetsklinikum Essen
      • Frankfurt am Main、德国、60488
        • Krankenhaus Nordwest
      • Chūōku、日本、104-0045
        • National Cancer Center Hospital
      • Kashiwa、日本、277-8577
        • National Cancer Center Hospital East
      • Kōtō City、日本、135-8550
        • The Cancer Institute Hospital of JFCR
      • Nagaizumi-cho,Sunto-gun、日本、411-8777
        • Shizuoka Cancer Center
      • Bordeaux、法国、33 076
        • Institut Bergonie
      • Paris、法国、75248
        • Institut Curie
      • Villejuif、法国、94800
        • Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
    • California
      • Santa Monica、California、美国、90404
        • UCLA
    • Colorado
      • Aurora、Colorado、美国、80045
        • University of Colorado Health Hospital
      • Denver、Colorado、美国、80218
        • Sarah Cannon Research Institute at HealthOne
    • Florida
      • Lake Mary、Florida、美国、32746
        • Florida Cancer Specialists ORLANDO/DDU
      • Miami、Florida、美国、33136
        • University of Miami
    • Illinois
      • New Lenox、Illinois、美国、60451
        • University of Chicago
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • Dana-Farber Cancer Institute
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital
    • New York
      • New York、New York、美国、10032
        • Columbia University Medical Center
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus、Ohio、美国、43210
        • Ohio State University Hospital
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • Sarah Cannon Research Institute
      • Nashville、Tennessee、美国、37232-6307
        • Vanderbilt-Ingram Cancer Center
      • Nashville、Tennessee、美国、37203
        • SCRI Oncology Partners
    • Texas
      • Houston、Texas、美国、77030-4009
        • MD Anderson Cancer Center
    • Virginia
      • Fairfax、Virginia、美国、22031
        • USO-Virginia Cancer Specialists, PC
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • Medical College of Wisconsin
      • Barcelona、西班牙、08035
        • Hospital Universitari Vall d'Hebron
      • Madrid、西班牙、28040
        • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
      • Ilsandong-gu、韩国、10408
        • National Cancer Center
      • Seoul、韩国、03722
        • Severance Hospital, Yonsei University Health System
      • Suwon、韩国、16247
        • The Catholic University of Korea, St. Vincent's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration:

    • Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)
    • Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
    • Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
    • Phase 1b expansion: Part C: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
  • Prior Systemic Therapy Criteria:

    • Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.
    • Phase 1b expansion (Part A): Participants must have received at least one line of therapy for advanced or metastatic disease.
    • Phase 1b expansion (Part C): Participants may be treatment naïve or have received therapy for advanced or metastatic disease
  • Measurability of disease

    • Phase 1a dose escalation (excluding backfill): measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)
    • Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion Criteria:

  • Participants with known or likely loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations
  • Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)
  • Participants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement
  • Participants with history of increased risk of prolonged QT or significant arrythmia
  • Significant cardiovascular disease
  • Participants with active and/or treated for an additional primary malignancy within 2 years prior to enrolment
  • Participants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention
  • Participants with history of active autoimmune diseases, history of allogenic stem cell/organ transplant or compromised immune system within past 2 years (Part C only)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:LY4050784 (Phase 1a - Dose Escalation)

Escalating doses of LY4050784 administered orally.

Oral

实验性的:LY4050784 (Phase 1b - Dose Optimization/Part A)

Comparing 2 or more doses (evaluated during dose escalation) of LY4050784 administered orally.

Oral

实验性的:LY4050784 (Phase 1b - Dose Expansion/Part B)

LY4050784 administered orally.

Oral

实验性的:LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C1

LY4050784 administered orally in combination in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.

Oral

Administered IV.

实验性的:LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2a

LY4050784 administered orally in combination in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.

Oral

Administered IV.

Administered IV.

Administered IV.

Administered IV.

实验性的:LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2b

LY4050784 administered orally in combination in combination with pembrolizumab, paclitaxel/nab-paclitaxel and carboplatin administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.

Oral

Administered IV.

Administered IV.

Administered IV.

Administered IV.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)
大体时间:Up to Approximately 48 Months or 4 Years

A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module

Up to Approximately 48 Months or 4 Years
Phase 1a: To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of LY4050784
大体时间:Up to Approximately 48 Months or 4 Years

Number of participants with dose-limiting toxicities (DLTs)

Up to Approximately 48 Months or 4 Years
Phase 1b: To assess the antitumor activity of LY4050784 Monotherapy: Overall response rate (ORR)
大体时间:Up to Approximately 48 Months or 4 Years

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

Up to Approximately 48 Months or 4 Years
Phase 1b (Dose optimization only): To confirm the RP2D/optimal dose based on safety and efficacy of LY4050784
大体时间:Up to Approximately 48 Months or 4 Years

A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module, ORR and Duration of Response (DOR) per Investigator

Up to Approximately 48 Months or 4 Years
Phase 1b (Combination cohorts/Part C): To assess the safety and tolerability of LY4050784 when administered in combination with other anticancer agents
大体时间:Up to Approximately 48 Months or 4 Years

A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module

Up to Approximately 48 Months or 4 Years

次要结果测量

结果测量
措施说明
大体时间
评估组合队列中LY4050784的PK特性:最大浓度(CMAX)PK:LY4050784的CMAX
大体时间:周期1(第8天)
周期1(第8天)
评估组合组中LY4050784的PK特性:最大浓度的时间(TMAX)PK:LY4050784的TMAX
大体时间:周期1(第8天)
周期1(第8天)
评估组合队列中LY4050784的PK特性:浓度与时间曲线的面积(AUC)
大体时间:周期1(第8天)
周期1(第8天)
To characterize the pharmacokinetics (PK) properties of LY4050784: Maximum Concentration (Cmax)
大体时间:Cycle 1 (Day 8)

PK: Cmax of LY4050784

Cycle 1 (Day 8)
To characterize the PK properties of LY4050784: Time to Maximum Concentration (Tmax)
大体时间:Cycle 1 (Day 8)

PK: Tmax of LY4050784

Cycle 1 (Day 8)
To characterize the PK properties of LY4050784: Area under the concentration versus time curve (AUC)
大体时间:Cycle 1 (Day 8)

PK: AUC of LY4050784

Cycle 1 (Day 8)
Phase Ia: To evaluate the preliminary antitumor activity of LY4050784: Overall response rate (ORR)
大体时间:Up to Approximately 48 Months or 4 Years

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

Up to Approximately 48 Months or 4 Years
To evaluate the preliminary antitumor activity of LY4050784: Duration of response (DOR)
大体时间:Up to Approximately 48 Months or 4 Years

DOR per investigator assessed RECIST 1.1

Up to Approximately 48 Months or 4 Years
To evaluate the preliminary antitumor activity of LY4050784: Time to response (TTR)
大体时间:Up to Approximately 48 Months or 4 Years

TTR per investigator assessed RECIST 1.1

Up to Approximately 48 Months or 4 Years
To evaluate the preliminary antitumor activity of LY4050784: Disease control rate (DCR)
大体时间:Up to Approximately 48 Months or 4 Years

DCR per investigator assessed RECIST 1.1

Up to Approximately 48 Months or 4 Years
To evaluate the preliminary antitumor activity of LY4050784: Progression free survival (PFS)
大体时间:Up to Approximately 48 Months or 4 Years

PFS per investigator assessed RECIST 1.1

Up to Approximately 48 Months or 4 Years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年9月19日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2024年8月16日

首先提交符合 QC 标准的

2024年8月16日

首次发布 (实际的)

2024年8月20日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅